Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation

BACKGROUND: The treatment of multiple myeloma (MM) has evolved significantly in the past decade, and new drug combinations have improved the response rates and prolonged survival. Studies comparing different induction chemotherapy regimens have shown that triple combinations have better results than...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Hematol Transfus Cell Ther
Egile Nagusiak: Crusoe, Edvan De Queiroz, Higashi, Fabiana, Martinez, Gracia, Bittencourt, Rosane, Pinto Neto, Jorge Vaz, Sousa, Lais, Santucci, Rodrigo, Magalhães, Roberto José Pessoa, Colli, Gilberto, Nunes, Renata Ferreira Marques, Ribeiro, Glaciano, Nicacio, Jandir, Zanella, Karla Richter, Kutner, Jose Mauro, Magalhaes, Andre, Leao, Danielle, Hallack Neto, Abrahão Elias, Braga, Walter, Souza, Emanuella G, Guimaraes, Antonio Julio A.M., Durigon, Giovanna Steffenello, Laks, Dani, Maiolino, Angelo, Hungria, Vania Tietsche de Moraes
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Sociedade Brasileira de Hematologia e Hemoterapia 2020
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7248497/
https://ncbi.nlm.nih.gov/pubmed/31537476
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.htct.2019.05.004
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak